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The purpose of lowering high blood pressure is to prevent
morbidity and mortality from hypertensive complications, such
as heart attack, stroke, renal failure, and heart failure. The
Veterans Administration studies in the 1960s proved beyond
doubt that treating hypertension with thiazides and β-blockers
(the drugs available at that time) significantly diminished the
rates of strokes, renal failure, and heart failure, although the
decrease in the rate of myocardial infarcts did not reach
statistical significance. It has been estimated that a
10–15 mmHg fall in systolic blood pressure should lead to a
15% reduction in relative risk for heart attack and to a 40%
reduction for stroke [1].
Effects of antihypertensive agents
With the advent of new classes of antihypertensive agents,
the emphasis shifted from efficacy in lowering blood
pressure, which is taken for granted, to potential to protect
against end-organ damage. Controlled clinical trials have
indicated that drugs from different classes have different
neurohumoral and metabolic profiles, which might enhance
or partially offset the benefits from blood pressure lowering
per se. For example, thiazides and β-adrenergic blockers
have been reported to further increase insulin resistance, and
hence to accentuate the dysmetabolic syndrome that
commonly accompanies essential hypertension [2,3]. On the
contrary, α1-adrenergic blockers and angiotensin-converting
enzyme (ACE) inhibitors have been reported to improve
insulin sensitivity and the lipid profile [4], whereas calcium-
channel blockers were found to be metabolically neutral. In
terms of neurohormonal changes, the stimulation of the
renin–angiotensin and sympathetic systems associated with
the use of diuretics and dihydropyridines should be
detrimental to end organs, whereas angiotensin blockers and
sympathetic blockers should be beneficial to them. Several
such effects that are theoretically considered to be beneficial
have been used as ‘surrogate endpoints’ in the absence of
firm data on morbidity and mortality.
Improvement in surrogate endpoints may be encouraging
but is not always predictive of real endpoints, and should
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Abstract
The lowering of high blood pressure is supposed to protect target organs from hypertensive damage.
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial was designed to
compare the cardioprotective properties of three antihypertensives from different classes (lisinopril,
amlodipine and doxazosin) with chlorthalidone. Despite effective blood pressure lowering and a
favorable metabolic profile, the doxazosin arm of the trial had a significantly higher relative risk of
cardiovascular disease and heart failure compared with the chlorthalidone arm. This article speculates
on possible causes for this unexpected result and suggests that the culprit may be accentuation of the
vascular effects of vasopressin, which are maximized under α-adrenergic blockade. These findings may
have implications for the large number of older men who receive monotherapy with α-blockers for
treatment of prostatic symptoms.
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not be sufficient to influence clinical decisions. This was
shown repeatedly by recent trials (e.g. with estrogen
replacement or various antioxidants), where amelioration in
various markers did not result in improved cardiovascular
outcomes [5]. Nevertheless, clinical trials on selected
subpopulations as well as meta-analyses of pooled data
suggest that, at levels producing a similar blood pressure
lowering effect, β-blockers were cardioprotective and ACE
inhibitors were both cardioprotective and nephroprotective,
while calcium-channel blockers might offer better protection
from stroke [6].
ALLHAT
These newer classes have not strictly speaking been proven
to reduce morbidity and mortality from hypertension, as they
could not ethically be tested against placebo. They could,
however, be tested against ‘the gold standard’, a thiazide that
has been proven to reduce morbidity and mortality in the
placebo-controlled trials. This is what led to the
Antihypertensive and Lipid Lowering Treatment to Prevent
Heart Attack Trial (ALLHAT) [7]. The double-blind, active-
controlled component of the ALLHAT was designed to
determine whether the rate of the primary outcome (a
composite of fatal myocardial infarcts and nonfatal coronary
events) would be different in high-risk older patients treated
with a drug from each one of three classes of
antihypertensives, an ACE inhibitor (lisinopril), a calcium
blocker (amlodipine), or an α1-adrenergic blocker
(doxazosin), compared with patients treated with a thiazide
diuretic (chlorthalidone).
The trial started in February 1994 and, after an interim
analysis in January 2000, an independent review committee
recommended that the doxazosin arm be discontinued. This
was because, compared with chlorthalidone, doxazosin had a
significantly higher relative risk of stroke (1.19) and of
combined cardiovascular disease (relative risk = 1.25), and a
more than double risk of congestive heart failure (relative
risk = 2.04) [8].
This unexpected outcome sparked a lot of discussion,
dismay, and speculation. There was dismay that, once more,
improvement in surrogate endpoints (blood pressure, lipid
profile, and other parameters of the dysmetabolic syndrome)
did not translate into favorable outcomes. There was
speculation on what concurrent changes might have over-
ridden the benefits of those improvements. We would like to
add our own plausible, although speculative, explanation for
these findings.
Explaining the doxazosin findings in the
ALLHAT
In addition to the renin–angiotensin and the sympathoadrenal
systems, arginine vasopressin (AVP) is the third major
systemic pressor hormone [9]. Its pressor function is partly
offset by its sensitizing influence on baroreflexes [10,11], not
fully apparent until the other two systems have been impaired
[12]. The importance of AVP to systemic or regional vascular
resistance cannot necessarily be predicted from the
circulating levels, as it is markedly increased after effective
sympathetic inhibition even in the absence of a further
increase in plasma levels. It can only be accurately estimated
from the response to a selective antagonist of the V1 type
receptors of AVP. Using such a pharmacologic probe, we
have found that the pressor action of AVP is maximized after
α1-adrenergic blockade [13]. Under certain conditions, AVP
becomes an important vasopressor factor in patients with
hypertension [12] and/or congestive heart failure [14]. Its
pressor influence is most apparent in patients with autonomic
insufficiency [15], such as diabetics or elderly individuals
[16]. Severe coronary constriction in response to AVP has
been proposed as the mechanism underlying a number of
acute ischemic events reported in the earlier literature
[17–19]. Although AVP does not seem to cause myocardial
ischemia under normal conditions [20], it may well do so
under chronic α1-adrenergic receptor blockade, especially in
older patients and in those with various degrees of
autonomic insufficiency [15,16].
The experimental evidence suggests that, in the presence of
functional baroreflexes, the small elevation in AVP following
α1-adrenergic receptor blockade [13] produces an increase
in systemic resistance with a strong reflex suppression of
cardiac output [21]. In the absence of an intact sympathetic
system, the vascular sensitivity to the vasoconstrictor effect
of AVP is enhanced by several orders of magnitude [10,21].
Accordingly, a combination of these factors could explain the
increased rates of ischemic cardiomyopathy and/or heart
failure in these patients.
Implications for the use of α α1-adrenergic
antagonists
What are the implications of the ALLHAT findings? One
implication is obviously that α1-adrenergic antagonists should
not be first choice antihypertensives, and this message has
already been widely disseminated. These agents are,
however, used extensively for their urodynamic properties in
patients with benign prostatic hypertrophy, many of whom
are older hypertensives (possibly with ischemic heart
disease) who prefer to use one drug as monotherapy for both
purposes. Indeed, doxazosin and terazosin are probably
much more popular for the treatment of prostatic symptoms
than for hypertension, and in this setting any cardiovascular
adverse effects from their widespread use would most
probably go unappreciated.
Competing interests
None declared.
References
1. Chalmers J, MacMahon S, Mancia G, Whitworth J, Beilin L,
Hansson L, Neal B, Rodgers A, Ni Mhurchu C, Clark T: 1999
World Health Organization–International Society of Hyperten-Available online http://cvm.controlled-trials.com/content/2/6/257
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
s
e
a
r
c
h
sion Guidelines for the management of hypertension. Guide-
lines sub-committee of the World Health Organization. Clin
Exp Hypertens 1999, 21:1009-1060.
2. Swislocki AL, Hoffman BB, Reaven GM: Insulin resistance,
glucose intolerance and hyperinsulinemia in patients with
hypertension. Am J Hypertens 1989, 2:419-423.
3. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL: Hyper-
tension and antihypertensive therapy as risk factors for type 2
diabetes mellitus. Atherosclerosis Risk in Communities
Study. N Engl J Med 2000, 342:905-912.
4. Lithell HO: Effect of antihypertensive drugs on insulin,
glucose, and lipid metabolism. Diabetes Care 1991, 14:203-
209.
5. Nabel EG: Coronary heart disease in women — an ounce of
prevention. N Engl J Med 2000, 343:572-574.
6. Neal B, MacMahon S, Chapman N: Effects of ACE inhibitors,
calcium antagonists, and other blood-pressure-lowering
drugs: results of prospectively designed overviews of ran-
domised trials. Blood Pressure Lowering Treatment Trialists.
Collaboration. Lancet 2000, 356:1955-1964.
7. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr,
Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM,
Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel
S, Black HR, Hawkins CM: Rationale and design for the Anti-
hypertensive and Lipid Lowering Treatment to Prevent Heart
Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hyper-
tens 1996, 9:342-360.
8. ALLHAT Collabortive Research Group: Major cardiovascular
events in hypertensive patients randomized to doxazosin vs
chlorthalidone; the antihypertensive and lipid-lowering treat-
ment to prevent heart attack trial (ALLHAT). JAMA 2000,
283:1967-1975.
9. Gavras H: Pressor systems in hypertension and congestive
heart failure: Role of vasopressin. Hypertension 1990, 16:587-
593.
10. Cowley AW Jr, Monos E, Guyton AC: Interaction of vasopressin
and the baroreceptor reflex system in the regulation of arter-
ial blood pressure in the dog. Circ Res 1974, 34:505-514.
11. Aylward PE, Floras JS, Leimbach WN Jr, Abboud FM: Effects of
vasopressin on the circulation and its baroreflex control in
healthy men. Circulation 1986, 73:1145-1154.
12. Ribeiro A, Mulinari R, Gavras I, Kohlmann O Jr, Ramos O, Gavras
H: Sequential elimination of pressor mechanisms in severe
hypertension in humans. Hypertension 1986, 8(suppl I):I-169-
I-173.
13. Gavras I, Hatinoglou S, Gavras H: The adrenergic system and
the release and pressor action of vasopressin. Hypertension
1986, 8(suppl II):II-163-II-167.
14. Creager MA, Faxon DP, Cutler SS, Kohlmann O Jr, Ryan TJ,
Gavras H: Contribution of vasopressin to vasoconstriction in
patients with congestive heart failure: comparison of vaso-
pressin to the renin–angiotensin system and the sympathetic
nervous system. J Am Coll Cardiol 1986, 7:758-765.
15. Williams TD, Da Costa D, Mathias CJ, Bannister R, Lightman SL:
Pressor effect of arginine vasopressin in progressive auto-
nomic failure. Clin Sci 1986, 71:173-178.
16. De Paula RB, Plavnik FL, Rodrigues CIS, De Assis Rocha Neves
F, Kohlmann O Jr, Ribeiro AB, Gavras I, Gavras H: Age and race
determine vasopressin participation in upright blood pressure
control in essential hypertension. Ann NY Acad Sci 1993, 689:
534-536.
17. Slotnik IL, Teigland JD: Cardiac accidents following vaso-
pressin injection (pitressin). JAMA 1951, 146:1126-1129.
18. Beller BM, Trevino A, Urban E: Pitressin-induced myocardial
injury and depression in a young woman. Am J Med 1971, 51:
675-679.
19. Kelly KJ, Stang JM, Mekhjian HS: Vasopressin provocation of
ventricular dysrhythmia. Ann Intern Med 1980, 92:205-206.
20. Glazier JJ, Faxon DP, Mills RM, Bresnahan MR, Ryan TJ, Gavras
H: Effect of arginine vasopressin on coronary and systemic
hemodynamics in man. Int J Cardiol 1989, 24:95-103.
21. Cowley AW Jr, Quillen EW, Skelton MM: Role of vasopressin in
cardiovascular regulation. Fed Proc 1983, 42:3170-3176.